Results 11 to 20 of about 1,426 (171)
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization [PDF]
Laryngoscope Investigative OtolaryngologyObjectives We evaluated the impact of teprotumumab therapy (TT) introduction on orbital decompression (OD) utilization for thyroid eye disease (TED) and compared rates of significant exophthalmos reduction (SER) and diplopia between TT and OD.
Nitish Kumar +5 more
doaj +3 more sources
Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms [PDF]
Case Reports in EndocrinologyGraves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy.
Soumya Chatterjee
doaj +3 more sources
Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report [PDF]
Case Reports in Ophthalmology, 2023 Teprotumumab is a novel insulin-like growth factor-1 receptor inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation. To date, an effective protocol for managing hearing loss in this
Tracy J. Lu +5 more
doaj +2 more sources
Teprotumumab for Thyroid Eye Disease: Mechanism, Clinical Efficacy, and Current Challenges [PDF]
AntibodiesThyroid eye disease (TED) is a complex autoimmune disorder characterized by orbital inflammation and tissue remodeling. Teprotumumab, a fully human monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), represents a significant ...
Yuan Zong +7 more
doaj +3 more sources
Reactions Weekly, 2021 Teprotumumab, a monoclonal antibody targeted against the insulin-like growth factor 1 (IGF-1) receptor, was recently approved by the United States Food and Drug Administration for the treatment of thyroid eye disease (TED).
Bryan J. Winn, Robert C. Kersten
core +4 more sources
Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study [PDF]
Endocrine ConnectionsTeprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued
Maxim John Levy Barnett +5 more
doaj +2 more sources
How to manage thyroid eye disease: recent advances – a narrative review [PDF]
Drugs in ContextThyroid eye disease (TED) is a complex autoimmune disorder and the most common extrathyroidal manifestation of Graves’ disease, characterized by orbital inflammation, tissue remodelling, and varying degrees of functional and cosmetic impairment. Although
Georgios K Markantes +4 more
doaj +2 more sources
Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy [PDF]
European Thyroid JournalBackground: In 2021, the European Group on Graves’ orbitopathy (EUGOGO) published clinical practice guidelines for the management of GO, and in 2022, the American and European Thyroid Associations published the ATA/ETA consensus statement on the same ...
Luigi Bartalena +4 more
doaj +2 more sources
Frontiers in EndocrinologyTeprotumumab has shown significant efficacy in treating Thyroid Eye Disease (TED), but its adverse effects require careful management. Key reactions include hearing impairment, hyperglycemia, and potential exacerbation of pre-existing inflammatory bowel ...
Yubo Tang, Haoru Jin
exaly +3 more sources
Orbital lymphocyte populations in three states of thyroid eye disease
American Journal of Ophthalmology Case Reports, 2023 Purpose: We report histopathologic orbital tissue analysis from three patients with thyroid eye disease (TED) – active, chronic, and post-teprotumumab to better characterize orbital cellular populations in these varying states of TED.
Shane M. Griffin, Rona Z. Silkiss
doaj +1 more source